Harmony Biosciences Holdings Inc

Research Harmony Biosciences Holdings Inc (HRMY) on Bullrun: valuation model: 17.4% undervalued, market cap USD 2.05B, P/E 14.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHRMY
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal17.4% undervalued
• Market capUSD 2.05B
• P/E14.2
• Financial periodFY2025
• RevenueUSD 868.45M
• Revenue growth21.5%
• Net incomeUSD 158.69M
• Free cash flowUSD 347.89M
• Gross margin77.2%

Valuation Snapshot

Bullrun's latest valuation model marks Harmony Biosciences Holdings Inc as 17.4% undervalued; latest market cap is USD 2.05B; P/E is 14.2.

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS);

Frequently asked questions

Is Harmony Biosciences Holdings Inc overvalued or undervalued?

Bullrun's valuation model currently marks Harmony Biosciences Holdings Inc as 17.4% undervalued.

What is Harmony Biosciences Holdings Inc's market cap?

Harmony Biosciences Holdings Inc's market capitalization is USD 2.05B.

What is Harmony Biosciences Holdings Inc's P/E ratio?

Harmony Biosciences Holdings Inc's price-to-earnings (P/E) ratio is 14.2.

What does Harmony Biosciences Holdings Inc do?

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.